(919) 237-4897 info@t3dtherapeutics.com

News + Events

Stay up to date with our latest news

T3D Therapeutics Reports Successful Pre-IND Meeting with the FDA

T3D Therapeutics announced today that it had a successful Type B Pre-Investigational New Drug (“Pre-IND) meeting on April 1st with the US Food and Drug Administration’s Division of Neurology Products, for T3D-959, a novel nuclear receptor agonist for the treatment of...

T3D Therapeutics adds Dr. Bruce Burnett to its Advisory Board

Bruce K. Burnett, PhD, RAC (US, EU) is Director of Regulatory Affairs at Duke Translational Medicine Institute. Dr. Burnett received his undergraduate degree in organic chemistry from the University of California, San Diego and his PhD in organic...